アス48は,レセプター活性化と放出抑制の双重機能のTREM2モデュレータで,クラスで初めてです.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。新しい薬であるAs48はTREM2シグナルを活性化し,その流出を防止し,マイクログリア機能と脳の修復メカニズムを強化することで,アルツハイマー病の新たな治療戦略を提供します.
科学分野
- 神経科学
- 免疫学
- 薬理学について
背景
- 骨髄細胞2 (TREM2) に発現するトリガリング受容体の機能障害は,アルツハイマー病 (AD) の病原性に関与しています.
- ADAM媒介によるTREM2流出は,受容体のシグナル伝達効率を低下させ,現在の治療法に挑戦しています.
研究 の 目的
- TREM2活性を調節する新しい小分子を特定する.
- アルツハイマー病の治療のためにTREM2シグナル伝達を強化し,受容体脱落を防止する治療法を開発する.
主な方法
- Affinity Selection-Mass Spectrometry (AS-MS) のスクリーニングにより,TREM2リガンドを特定する.
- 生物物理的検証,細胞検査 (SYKリン酸化,ファゴサイトーシス),分子ドッキング,分子動態シミュレーション.
- TREM2エクトドメインの脱落とプロテアゼの活性に対するAs48の効果の評価 (ADAM10/17).
主要な成果
- 新種の小分子であるAs48は,TREM1よりも高い親和性と選択性でTREM2と結合する.
- As48はTREM2アゴニストとして作用し,マイクログリアルファゴシトーシスとSYKのリン酸化を促進する.
- As48は,プロテアゼの活性に影響を及ぼさずに,割裂部位付近の形状制限によってTREM2の脱落を抑制する.
- As48は好ましい薬動性を示し,脳に浸透する可能性がある.
結論
- As48は,TREM2シグナル伝達を活性化し,その流出を抑制する最初の小分子です.
- As48は神経炎症とアルツハイマー病の薬剤発見の TREM2 調節における パラダイムシフトを表しています
- As48の二重作用メカニズムは,神経変性疾患の治療に重要な翻訳的関連性を提供します.
関連する概念動画
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...